The Global Multiple Cancer Monoclonal Antibodies Market Size is valued at 67.21 billion in 2023 and is predicted to reach 154.24 billion by the year 2031 at a 11.19% CAGR during the forecast period for 2024-2031.
Cancer monoclonal antibodies are specific antibodies with identical immune cells that are clones of a single parent cell directed to specific cellular targets. Thus, monoclonal antibodies are preciously customizable due to their unique nature and play a crucial role in treating target-specific cancerous cells. Therefore, monoclonal antibodies technology is proven to be more effective than other cancer therapies.
The increasing incidence of cancer disease among the population is driving the growth of the market. For instance, as per the World Health Organization, cancer is the second leading cause of death worldwide, accounting for around 9.6 million deaths in the year 2018. Multiple cancers, including lung cancer, colorectal cancer, prostate cancer, and liver cancer, are the most common types of cancer among men, while breast cancer, cervical cancer, colorectal cancer, and thyroid cancer are the most common among women. Additionally, increasing spending on research and development by multinational pharmaceutical companies is expected to create lucrative market growth. However, the high cost of treatment therapy and drug development may restrain the growth of the market.
The Global Multiple Cancer Monoclonal Antibodies market is segmented on the basis of product type, indication type, and region. Based on the service, the market is divided into Cetuximab, Nivolumab, Atezolizumab, Ramucirumab, Pembrolizumab, Pembrolizumab Companion Diagnostic, Ipilimumab, and Cancer Biosimilar Drugs (Bevacizumab, Trastuzumab, Nimotuzumab, etc.). On the basis of indication type, the market is divided into Lung Cancer, Bladder Cancer, Breast cancer, Endometrial cancer, Ovarian cancer, Oesophageal cancer, Prostate cancer, Multiple Myeloma, Lymphoma, Renal Cell Cancer, and Others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, Europe held the largest share of the market, followed by America and the Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of the forecast period
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 67.21 billion |
| Revenue Forecast In 2031 | USD 154.24 billion |
| Growth Rate CAGR | CAGR of 11.19% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Billion and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Product Type, Indication Type |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Abbvie, Amgen, Bayer HealthCare, Biogen Idec, Eli Lilly, Genmab, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, Roche, and Seattle Genetics, among others. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Multiple Cancer Monoclonal Antibodies Market Snapshot
Chapter 4. Global Multiple Cancer Monoclonal Antibodies Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Dynamics - Drivers
4.3. Challenges/Restraints
4.4. Market Trends
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Epidemiology Analysis -2020
4.7. Lung Cancer
4.8. Bladder Cancer
4.9. Breast cancer
4.10. Endometrial cancer
4.11. Ovarian cancer
4.12. Oesophageal cancer
4.13. Prostate cancer
4.14. Multiple Myeloma
4.15. Lymphoma
4.16. Renal Cell Cancer
4.17. Competitive Landscape & Market Share Analysis
4.18. Key Investments and Funding’s in Oncology 2019
4.19. COVID 19 Impact on Pharmaceutical and Oncology R&D Industry
Chapter 5. Market Segmentation 1: Product Types Estimates & Trend Analysis
5.1. Product Types & Market Share, 2019 & 2031
5.2. Market Size (Value)& Forecasts and Trend Analyses, 2019 to 2031 for the following Product Types:
5.2.1. Cetuximab
5.2.2. Nivolumab
5.2.3. Atezolizumab
5.2.4. Ramucirumab
5.2.5. Pembrolizumab
5.2.6. Pembrolizumab Companion Diagnostic
5.2.7. Ipilimumab
5.2.8. Cancer Biosimilar Drugs (Bevacizumab, Trastuzumab, Nimotuzumab, etc.)
Chapter 6. Multiple Cancer Monoclonal Antibodies Market Segmentation 2: Indication Types Estimates & Trend Analysis
6.1. Indication Types Analysis & Market Share, 2019 & 2031
6.2. Market Size (Value) & Forecasts and Trend Analyses, 2019 to 2031 for the following Indication Types:
6.2.1. Lung Cancer
6.2.2. Bladder Cancer
6.2.3. Breast cancer
6.2.4. Endometrial cancer
6.2.5. Ovarian cancer
6.2.6. Oesophageal cancer
6.2.7. Prostate cancer
6.2.8. Multiple Myeloma
6.2.9. Lymphoma
6.2.10. Renal Cell Cancer
6.2.11. Others
Chapter 7. Multiple Cancer Monoclonal Antibodies Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Product Types, 2024-2031
7.1.2. North America Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indication Types, 2024-2031
7.1.3. North America Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by country, 2024-2031
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Product Types, 2024-2031
7.2.2. Europe Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indication Types, 2024-2031
7.2.3. Europe Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) by country, 2024-2031
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Product Types, 2024-2031
7.3.2. Asia Pacific Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indication Types, 2024-2031
7.3.3. Asia Pacific Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) by country, 2024-2031
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Product Types, 2024-2031
7.4.2. Latin America Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indication Types, 2024-2031
7.4.3. Latin America Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) by country, (US$ Million) 2024-2031
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. MEA
7.5.1. MEA Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Product Types, 2024-2031
7.5.2. MEA Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indication Types, 2024-2031
7.5.3. MEA revenue Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) by country, (US$ Million) 2024-2031
7.5.3.1. South Africa
7.5.3.2. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances in Biosimilar Industry
8.2. Company Profiles
8.2.1. Abbvie
8.2.2. Amgen
8.2.3. Bayer HealthCare
8.2.4. Biogen Idec
8.2.5. Eli Lilly
8.2.6. Genmab
8.2.7. Gilead Sciences
8.2.8. GlaxoSmithKline
8.2.9. Novartis
8.2.10. Pfizer
8.2.11. Roche
8.2.12. Seattle Genetics
8.3. List of Other Prominent Players
Global Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) by Product Type
Global Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) Based on Indication Type
Global Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) Based on Region
Europe Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) by Country
North America Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) by Country
Asia Pacific Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) by Country
Latin America Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) by Country
Middle East & Africa Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) by Country